Page 3 of 5: studies 41 to 60 of 93, newest first. Back to the ketamine overview
International Journal of Advanced Research June 30, 2016 Samar Adel Asker, Shireen A. Mazroa, Youmna Sabri
Background:- Ketamine is commonly used as a dissociative anesthetic drug. However, some clinical studies suggested that ketamine ameliorated depressive symptoms in patients with major depression. Therefore,
arXiv Preprint Archive June 15, 2016 Eduardo C. Padovani preprint
One of the main goals of neuroscience is to understand how an organism's cognitive capacities or physiological states are potentially related to brain activities that involve the interaction of multiple brain structures and cortical areas. A key feature of functional brain networks is that they are modularly structured, and this modular architecture is regarded as accounting for a range of...
PLoS One June 14, 2016 Bryan L. Roth, Simon Gibbons, Warunya Arunotayanun et al. 153 citations
In this paper we determined the pharmacological profiles of novel ketamine and phencyclidine analogues currently used as 'designer drugs' and compared them to the parent substances via the resources of the National Institute of Mental Health Psychoactive Drug Screening Program. The ketamine analogues methoxetamine ((RS)-2-(ethylamino)-2-(3-methoxyphenyl)cyclohexanone) and 3-MeO-PCE...
Psychopharmacology June 11, 2016 K. Podkowa, Bartłomiej Pochwat, P. Brański et al.
Numerous preclinical and clinical studies have reported the rapid and sustained antidepressant effects of the NMDA receptor antagonist ketamine. Because ketamine induces several undesirable and dangerous effects, a variety of strategies have been suggested to avoid such effects. Here, we propose to enhance the sub-effective doses of ketamine by co-administration with the group II metabotropic...
Psychological Medicine June 10, 2016 Kenji Hashimoto 54 citations
Letter to the Editor: R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity Published online by Cambridge University Press: 10 June 2016 K. Hashimoto Show author details K.
The Journal of Clinical Psychiatry June 2016 Dawn F. Ionescu, Michaela B Swee, Kara J. Pavone et al.
Ketamine rapidly reduces thoughts of suicide in patients with treatment-resistant depression who are at low risk for suicide. However, the extent to which ketamine reduces thoughts of suicide in depressed patients with current suicidal ideation remains unknown. Between April 2012 and October 2013, 14 outpatients with DSM-IV-diagnosed major depressive disorder were recruited for the presence of...
Therapeutic Advances in Psychopharmacology June 2016 John Muller, Sahana Pentyala, James Dilger et al.
Recent evidence has suggested that the N-methyl-D-aspartate receptor antagonist ketamine shows significant therapeutic effects in major depression and bipolar disorder. This effect is especially important in treatment-resistant depression and depression with suicidal ideation. In this review we explain the mechanism of action, drug efficacy, and the side effects of ketamine; the antidepressive...
Psychopharmacology June 1, 2016 Anna Mutti, Sonia Aroni, Paola Fadda et al.
Recently, an increasing number of emergency cases due to a novel ketamine-like drug, methoxetamine (MXE), were reported in several countries. However, very little is known about the neuropsychopharmacological and reinforcing profile of this compound. Our study aims to investigate the effects of MXE on self-administration (SA) behaviour in comparison to ketamine and on dopaminergic transmission....
Current behavioral neuroscience reports June 1, 2016 Dawn F. Ionescu, George I. Papakostas
Traditional antidepressant medications generally take weeks-to-months to achieve effect. However, the breakthrough finding of ketamine's rapidly acting antidepressant properties has inspired a decade-and-a-half of progress towards the identification of treatments that work quickly-within hours-to-days. This paradigm-shift in the discovery of antidepressant therapies has significantly changed...
Psychiatry Research May 30, 2016 Chun Yang, Mei Han, Ji-Chun Zhang et al.
Clinical use of the rapid antidepressant drug ketamine is limited, due to psychotomimetic side effects. R-ketamine appears to be a potent, long-lasting and safer antidepressant, relative to S-ketamine (esketamine), since it is free of psychotomimetic side effects. Repeated, intermittent administration of esketamine (10mg/kg, once per week for 8-weeks), but not R-ketamine, caused loss of...
The International Journal of Neuropsychopharmacology May 27, 2016 G. Treccani, Liebenberg N. Nico, S. Tillmann et al.
Specific objective of the study: This study is aimed to investigate desipramine, venlafaxine and bupropion on depression and anxiety in mice. Methods used: We used a classic tricyclic antidepressant, desipramine; a serotonin-norepinephrine reuptake inhibitör, venlafaxine; a second-generation antidepressant agent that blocks centrally the reuptake of noradrenaline and dopamine, bupropion in...
The International Journal of Neuropsychopharmacology May 27, 2016 P. Jack, B. Massimiliano, Grazia di Capua et al.
Abstract Objective: One third of major depressive disorder (MDD) patients are unresponsive to antidepressant drugs, a sub-type known as treatment resistant depression (TRD). Acute intravenous administration of ketamine at sub-anaesthetic dosage is the only efficacious pharmacological treatment in TRD. Development of TRD preclinical assays to screen for more efficacious antidepressant drugs and...
Journal of Psychopharmacology May 25, 2016 Philip R. Corlett, Garry D Honey, P. Fletcher
In 2007, we proposed an explanation of delusion formation as aberrant prediction error-driven associative learning. Further, we argued that the NMDA receptor antagonist ketamine provided a good model for this process. Subsequently, we validated the model in patients with psychosis, relating aberrant prediction error signals to delusion severity. During the ensuing period, we have developed...
Biological Psychiatry May 12, 2016 Marc S. Lener, Mark J. Niciu, E. Ballard et al.
In patients with major depressive disorder (MDD) or bipolar disorder (BD), abnormalities in excitatory and/or inhibitory neurotransmission and neuronal plasticity may lead to aberrant functional connectivity patterns within large brain networks. Network dysfunction in association with altered brain levels of glutamate (Glu) and gamma-aminobutyric acid (GABA) have been identified in both animal...
Neuroscience Letters May 4, 2016 Tracey L Petryshen, Michael Lewis, Kelly A Dennehy et al.
Current medications for depression typically require weeks of treatment before significant clinical improvement is observed, and are only effective in a relatively small subset of patients. Recent human clinical studies have demonstrated that ketamine, an NMDA receptor antagonist, and scopolamine, a muscarinic acetylcholine receptor antagonist, produce rapid antidepressant responses within...
Brain Research Bulletin May 4, 2016 Rachel R. Horsley, Eva Lhotková, Kateřina Hájková et al. 38 citations
Methoxetamine (MXE) is a novel psychoactive compound (NPS) that emerged in 2010 as a substitute for the dissociative anaesthetic ketamine. MXE has a reputation of carrying a lower risk of harm than ketamine, however a number of deaths have been reported. Currently very little is known about the psychopharmacological effects of this compound or its toxicity; therefore we tested, in Wistar rats,...
Biological Psychiatry May 1, 2016 D. M. Katz, F. Menniti, R. J. Mather
In 2007, Adrian Bird and his colleagues at the University of Edinburgh published a groundbreaking study demonstrating that Rett syndrome (RTT), a severe genetic neurodevelopmental disorder, is reversible in mouse models of the disease (1). Using Cre-Lox technology, the Bird group engineered a mouse in which the disease-causing gene, Mecp2, could be reversibly inactivated. Animals born with the...
Evidence-Based Mental Health May 2016 Jaclyn Schwartz, James W. Murrough, Dan V. Iosifescu
Approximately one-third of patients with major depressive disorder (MDD) do not respond to existing antidepressants, and those who do generally take weeks to months to achieve a significant effect. There is a clear unmet need for rapidly acting and more efficacious treatments. We will review recent developments in the study of ketamine, an old anaesthetic agent which has shown significant...
BJPsych Open May 1, 2016 Gin S. Malhi, Yulisha Byrow, Frederick Cassidy et al. 31 citations
SUMMARY: The appeal of ketamine - in promptly ameliorating depressive symptoms even in those with non-response - has led to a dramatic increase in its off-label use. Initial promising results await robust corroboration and key questions remain, particularly concerning its long-term administration. It is, therefore, timely to review the opinions of mood disorder experts worldwide pertaining to...
Nature April 24, 2016 Panos Zanos, Ruin Moaddel, Patrick J. Morris et al. 1,602 citations
Major depressive disorder affects around 16 per cent of the world population at some point in their lives. Despite the availability of numerous monoaminergic-based antidepressants, most patients require several weeks, if not months, to respond to these treatments, and many patients never attain sustained remission of their symptoms. The non-competitive, glutamatergic NMDAR (N-methyl-d-aspartate...